The Challenges of Treating Patients with Cancer During the COVID-19 Pandemic


Jeffrey Schneider, MD, and Marc Braunstein, MD, PhD, spoke about their recent article published in the journal ONCOLOGY® regarding the management of patients with cancer during the COVID-19 pandemic.

In an article published in the journal ONCOLOGY®, researchers at NYU Winthrop Hospital presented considerations for the management of patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.

One particular challenge discussed in the paper included balancing the benefits of oncology-directed treatment with the implicit increased risks of COVID-19 infection. Notably, the authors indicated that clinical trials have been initiated to specifically evaluate the changes that have occurred within this particular patient population, including 16 clinical trials which were either actively recruiting cancer patients or planning imminent recruitment to address specific concerns related to cancer management during the COVID-19 pandemic.

“As more data come to light on the pathophysiology of the novel coronavirus, we will be able to better modify cancer care and treatment protocols to minimize risks to our patients,” the authors of the article wrote. “Until then, best practice in oncology care mandates strict infection control processes and informed conversations with our patients in which we discuss the risks and benefits of modifying standard approaches in order to decrease the risk of COVID-19 infection and its complications.”

In an interview with CancerNetwork®, co-authors Jeffrey Schneider, MD, chief of the division of Oncology/Hematology and director of the Thoracic Lung Cancer Program at NYU Winthrop Hospital, and Marc Braunstein, MD, PhD, assistant professor of medicine and program director of the Hematology/Oncology Fellowship at NYU Long Island School of Medicine and NYU Winthrop Hospital, discussed the paper further and what they have discovered through their own experiences in treating patients with cancer throughout the pandemic.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.


Huang J, Rohatgi A, Schneider J, Braunstein M. Considerations for the Management of Oncology Patients During the COVID-19 Pandemic. ONCOLOGY®.

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content